PAINWeek 2018

Dr Zacharoff offered several tips to PAINWeek attendees to help improve their communication with patients.

A clinical pathway designed to reduce variations in opioid prescriptions for acute pain in children discharged after orthopedic surgery, was found to be effective in reducing prescriptions while maintaining analgesia.

DFN-11, a 3 mg subcutaneous (SC) sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine, as it was found to have a lower incidence of side effects and injection site reactions.

Perioperative and emergency department use of non-steroidal anti-inflammatory drugs as part of a multimodal analgesia regimen may improve pain control in pediatric populations and avoid opioid-related adverse events.

Dr Prasad highlights the importance of interdisciplinary approaches to the management of chronic pain.

Lasmiditan was found to be more effective compared with placebo in eliminating pain and other symptoms associated with headache in individuals with migraine.

Nucynta extended-release (ER) may be associated with lower rates of abuse compared with other ER opioid medications.

Clinicians are reducing or discontinuing opioid therapy for patients in light of the 2016 guidelines for opioid prescribing by primary care physicians issued by the CDC.

Dr Harden provides an overview of the use of ketamine as an analgesic and its associated side effects.

Oxycodone ARIR (RoxyBondTM), a novel abuse-deterrent formulation of immediate-release oxycodone, may have comparable safety and efficacy to IR oxycodone.